A partnership roundup covers deals from IntraGel Therapeutics/UroGen Pharma and Lupin/Tenpoint Therapeutics, FDA approves ...
UroGen Pharma has invested in IntraGel Therapeutics and secured an exclusive option to license Tumocure, and Lupin's ...
FDA approval in adult FOP targets disease-driving Activin A biology, addressing progressive heterotopic ossification that ...
Pharmaceutical reshoring is constrained by supplier qualification, process validation, FDA compliance readiness, workforce ...
Heidi Overton, a UNM-trained physician with Johns Hopkins general surgery training, was selected for FDA commissioner after ...
Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...
How drug pricing, tariffs, and manufacturing decisions are becoming connected. For years, pharmaceutical companies could ...
President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for ...
Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the ...
Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...
Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the leaders from the rest.
Exclusive ex-China rights extend to up to 10 partnered biosimilar programs, positioning Sandoz to shape development and registration strategy using early commercial and market-access input. Financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results